Ads
related to: multiple myeloma- Contact a Representative
For Questions and Information
About This Treatment
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Contact a Representative
Search results
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated ...
Benzinga via Yahoo Finance· 4 hours agoThe data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. On...
...Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep,...
Benzinga via Yahoo Finance· 7 hours agoMonday, Johnson & Johnson (NYSE:JNJ) announced longer-term data from Phase 1/2 MajesTEC-1 study of...
GSK blood cancer drug nearly halves risk of death in late-stage trial
Reuters via Yahoo News· 2 days agoGSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared...
Quadruplet Regimens Have Become Standard for Multiple Myeloma
MedPage Today· 4 days agoWhile triplet regimens were once standard for newly diagnosed multiple myeloma, more recent studies...
Advances in CAR T-Cell Therapy for Multiple Myeloma
MedPage Today· 4 days agoB-cell maturation antigen (BCMA)-directed CAR T-cell therapies are now established options for treating multiple myeloma after relapse, but efforts are...
EXCLUSIVE: Telo Genomics' Smoldering Multiple Myeloma Prognostic Test Predicts Risk Of Disease...
Benzinga via Yahoo Finance· 4 days agoOn Thursday, Telo Genomics Corp (OTC:TDSGF) announced that the manuscript “Three-dimensional...
GSK builds case for return of multiple myeloma drug Blenrep
BioPharma Dive via Yahoo Finance· 2 days agoStudy results showed the antibody-drug conjugate helped stave off disease progression better than a...
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma - Blood...
Nature· 4 days agoB-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective ...
FDA accepts Sanofi’s Sarclisa sBLA for priority review
Pharmaceutical Technology via Yahoo Finance· 7 days agoSanofi is seeking approval for Sarclisa, a monoclonal antibody, in combination with bortezomib,...
Cancer-fighting antibodies inject chemo directly into tumor cells, upping effectiveness
NBC Universal via AOL· 2 days agoBy attaching a chemotherapy drug to an antibody, doctors are able to deliver more potent...
Ad
related to: multiple myeloma